Highlights
Short-term duodenal infusion of recombinant RORDEP1 (r-RORDEP1) was safe and well tolerated in 17 healthy, normal-weight men.
Compared with placebo, r-RORDEP1 produced an early rise in plasma glucagon-like peptide-1, insulin, and C-peptide, while lowering gastric inhibitory polypeptide and glucose after a standardized liquid mixed meal.
